BAMATE Drug Patent Profile
✉ Email this page to a colleague
When do Bamate patents expire, and when can generic versions of Bamate launch?
Bamate is a drug marketed by Alra and is included in one NDA.
The generic ingredient in BAMATE is meprobamate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the meprobamate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bamate
A generic version of BAMATE was approved as meprobamate by INVAGEN PHARMS on February 27th, 2008.
Summary for BAMATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Patent Applications: | 4,157 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BAMATE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BAMATE
US Patents and Regulatory Information for BAMATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alra | BAMATE | meprobamate | TABLET;ORAL | 080380-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Alra | BAMATE | meprobamate | TABLET;ORAL | 080380-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
